Trending News
News
News
Agilent Technologies Appoints IMGM Laboratories Certified Service Provider for Gene Expression Microarrays
IMGM achieved Agilent-certified status after completing training and passing a rigorous series of assessments.
News
Key to Treating Cancer May be Finding its Original Cell
Cancer biologists are turning their attention to learn how tumor growth might be stopped at the earliest opportunity.
News
Dynavax and Merck Announce Phase 3 Trial with Investigational Hepatitis B Vaccine Met its Primary Endpoint
HEPLISAV, an investigational HBV vaccine, is being jointly developed by Dynavax and Merck for use in adults and in patients with end stage renal disease.
News
Designer RNA Fights High Cholesterol, Researchers Find
Small RNA can interfere with cholesterol metabolism, reducing harmful cholesterol by two-thirds in pre-clinical tests.
News
Childhood Brain Tumor Traced to Normal Stem Cells Gone Bad
Medulloblastomas are driven by mutation-altered stem/progenitor cells of the normal brain study shows.
News
Cancer Researchers and Oncologists Offer a Clinical Trial for Multiple Myeloma Patients
Researchers are studying the effects of experimental treatments on living tumor cells taken from multiple myeloma patients undergoing a routine diagnosis.
News
Alnylam Forms Collaboration with Max Planck Institute to Investigate Biological Mechanisms for Cellular Uptake of RNAi Therapeutics
Company to work with leading laboratory in cell trafficking field as part of continued commitment to advance research on delivery of RNAi therapeutics.
News
Agilent Technologies Microarrays Selected by Wellcome Trust Case Control Consortium
Landmark human genome copy number variation study of 19,000 DNA samples aimed at genetic causes of 11 widespread diseases.
News
Human Rhinovirus Phase IIa Clinical Trial Commences
Biota Holdings has commenced the dosing in the first Phase IIa challenge study of BTA798, an orally delivered and potent inhibitor of human rhinovirus.
News
Hollis-Eden Commences Phase I/II Clinical Trial with TRIOLEX™ in Rheumatoid Arthritis Patients
The purpose of the Phase I/II clinical trial is to evaluate the safety and tolerance of TRIOLEX when administered orally for 28 days at three different dose levels.
Advertisement